Generate Biomedicines, Inc.

Generate Biomedicines, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Generate Biomedicines, Inc. has 128.27M shares outstanding.

As of June 30, 2026, Generate Biomedicines, Inc. maintains a current ratio of 8.30, meaning it holds 8.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.73, indicating elevated leverage, while an interest coverage ratio of -441.23 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 353,575.91 in revenue per employee across its workforce of 312.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Generate Biomedicines, Inc. recorded 925,994.80 in income tax expense.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Generate Biomedicines, Inc. holds 7.99B in cash and equivalents against 1.09B in total debt, resulting in a net debt position of -2.36B. Total book value stands at 7.97B, with working capital of 7.23B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. After subtracting -16.30M in capital expenditures, free cash flow totaled -1.03B - equivalent to -8.02 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,134.21 and net profit margin of -1,065.17 provide insight into operational efficiency.